PLOS Medicine Impact Factor

The current 9.9 JIF is down from 15.8 in the 2023 data year and unchanged from 9.9 in the 2024 data year. That pattern matters because the old 15.8 spike can make the current number look like a journal collapse. A better read is citation normalization after COVID-era clinical and public-health papers moved through the two-year citation window.

Source limitation: this table is a submission-decision guardrail, not a formal historical citation table. Use Clarivate Journal Citation Reports directly before citing old year-by-year values in a grant, CV, promotion packet, or publisher-facing document.

PLOS Medicine is a Q1 medicine journal, but exact rank language is easy to misuse. Some sources show a broad medicine field rank. Older Manusights pages used a General and Internal Medicine rank from a prior release. Those are not interchangeable. For an author deciding whether to submit, the durable signal is Q1 plus the journal's scope. For formal reporting, use Journal Citation Reports directly.

The title boundary matters too. The database abbreviation is PLOS MED, with pISSN 1549-1277 and eISSN 1549-1676. Do not mix it with PLOS ONE, PLOS Biology, PLOS Global Public Health, or the broader Public Library of Science publisher portfolio.

The 9.9 JIF tells you PLOS Medicine remains a serious open-access medical target, but it does not tell you that the journal is simply a lower-impact version of JAMA, The BMJ, or The Lancet. PLOS Medicine has its own editorial shape: open access, broad medical relevance, policy interest, international audience, and a stated preference for work that can inform patient care, public policy, or clinical research agendas.

For authors, the number should change two decisions. First, do not treat PLOS Medicine as a prestige fallback after a flagship rejection unless the manuscript already has a general medical argument. A narrow specialty paper can be rigorous and still look wrong for the journal. Second, do not confuse open access with a lower editorial bar. PLOS Medicine says only about 10% of initial submissions ultimately progress to publication, and its public criteria emphasize substantial advance, interest beyond specialists, and clear implications.

The five-year JIF of 11.0 is useful because it suggests PLOS Medicine papers can continue accumulating citations beyond the immediate two-year window. That fits trials, systematic reviews, large observational studies, global-health analyses, and policy-relevant work. It is less helpful for small pilot studies, local audits, mechanistic papers without patient-level evidence, or manuscripts whose main contribution needs a specialist audience to decode.

PLOS is a publisher portfolio, not one editorial standard. PLOS Medicine, PLOS ONE, and PLOS Biology can all be reputable targets, but the metric and fit logic are different.

This distinction prevents a common wrong turn. A disease-adjacent mechanistic paper does not automatically belong in PLOS Medicine because it mentions patients. If the main claim is biological mechanism, PLOS Biology or a specialty journal may be cleaner. A methodologically sound but incremental clinical dataset may be better suited to the soundness-first PLOS journal or BMJ Open than to PLOS Medicine. The right target depends on the manuscript's claim, not just the highest PLOS impact factor.

For upload mechanics and article-type requirements, use the PLOS Medicine author instructions. For a separate reputation and fit verdict, use Is PLOS Medicine a good journal?.

In our pre-submission review work on PLOS Medicine-targeted manuscripts, three specific failure patterns show up repeatedly before the impact factor becomes useful. These are not generic open-access problems. They are the points where a paper can be scientifically credible but still fail to read like PLOS Medicine.

PLOS Medicine implication missing from the abstract. The official scope says the journal wants work with clear implications for patient care, public policy, or clinical research agendas. The weak version is an abstract that reports a statistically significant result but leaves the clinical or policy consequence for the discussion. PLOS Medicine editors should not have to infer the audience from a paragraph buried near the end. The title, abstract conclusion, and first introduction page need to show what changes for clinicians, policymakers, or research agendas.

PLOS Medicine international audience not visible in the methods. PLOS Medicine says relevance to an international audience matters. Single-country, single-system, or narrow cohort studies are not impossible, but the methods and limitations need to explain why the evidence travels. We often see strong datasets whose abstract sounds global while the sample, inclusion criteria, subgroup table, and setting description remain local. That mismatch makes the manuscript look less like a PLOS Medicine paper and more like a specialty or regional journal paper.

PLOS Medicine reproducibility package weaker than the claim. PLOS emphasizes ethics, data sharing, transparency in review and publication, and reusable open-access research. The weak version is a strong claim with a thin data-availability statement, vague protocol reference, missing trial registration, incomplete consent or ethics language, or supplemental methods that do not let a reviewer reconstruct the analysis. For PLOS Medicine, the data, protocol, ethics, and reporting statements have to support the public-health or clinical weight of the conclusion.

The repair is usually visible in five places: the abstract conclusion, the last paragraph of the introduction, the methods table, the data and ethics statements, and the cover letter. If those components tell one story, the 9.9 JIF becomes a useful target signal. If they disagree, the page's metric is a distraction.

A PLOS Medicine journal-fit check can test whether the manuscript's abstract, methods, data-availability package, and cover letter support this target before upload.

PLOS Medicine at 9.9 is still a high-selectivity open-access medical target. Its value is not only the citation number. The journal combines Q1 status, a broad medical audience, open access, a visible policy and global-health posture, and public criteria that are unusually explicit about patient care and public policy implications.

The strongest use of this page is to place PLOS Medicine in the target ladder, then stop metric-chasing. If the manuscript has broad medical consequence, patient or policy relevance, and a complete transparency package, PLOS Medicine can be a rational target. If the manuscript is narrow, local, mechanistic, or mostly prestige-seeking, the same 9.9 number should push you toward a better-fit journal rather than toward a weak PLOS Medicine submission.